Characteristics and Treatment Outcomes of Retreatment Tuberculosis Patients in Benin
- PMID: 27110400
- PMCID: PMC4823506
- DOI: 10.1155/2016/1468631
Characteristics and Treatment Outcomes of Retreatment Tuberculosis Patients in Benin
Abstract
Objective. To determine among retreatment tuberculosis patients in Benin baseline characteristics, culture, and drug sensitivity testing (DST) results and treatment outcomes. Materials and Methods. A retrospective national cohort study of all retreatment tuberculosis patients in Benin in 2013 using registers and treatment cards. Results. Of 3957 patients with tuberculosis, 241 (6%) were retreatment cases. Compared to new pulmonary bacteriologically confirmed tuberculosis (NPBCT) patients, there were significantly higher numbers of males (P = 0.04), patients from "Atlantique-Littoral" (P = 0.006), patients aged 45-64 years (P = 0.007), and HIV-positive patients (P = 0.04) among those retreated. Overall, 171 (71%) patients submitted sputum for DST, of whom (163) 95% were positive for Mycobacterium tuberculosis on Xpert MTB/RIF and/or culture and 17 (10%) were rifampicin resistant (9 with MDR-TB and 8 monoresistant to rifampicin). For those without MDR-TB (n = 224), treatment success was 93%. Worse outcomes occurred in those with unknown HIV status (RR: 0.27; 0.05-1.45; P < 0.01) while better outcomes occurred in those who relapsed (RR: 1.06, 95 CI: 1.02-1.10, P = 0.04). Conclusion. In 2013, a high proportion of retreatment patients received DST. Treatment success was good although more needs to be done to systematically increase the final follow-up smear examination. Reasons of high losses to follow-up from "Oueme-Plateau" should be investigated.
Similar articles
-
Xpert MTB/RIF for rapid detection of rifampicin-resistant Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia.Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S48-S49. doi: 10.1016/j.ijmyco.2016.09.002. Epub 2016 Nov 5. Int J Mycobacteriol. 2016. PMID: 28043605
-
Use of GeneXpert Mycobacterium tuberculosis/rifampicin for rapid detection of rifampicin resistant Mycobacterium tuberculosis strains of clinically suspected multi-drug resistance tuberculosis cases.Ann Transl Med. 2016 May;4(9):168. doi: 10.21037/atm.2016.05.09. Ann Transl Med. 2016. PMID: 27275481 Free PMC article.
-
Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.PLoS One. 2015 Jul 16;10(7):e0132514. doi: 10.1371/journal.pone.0132514. eCollection 2015. PLoS One. 2015. PMID: 26181578 Free PMC article.
-
Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China.BMC Infect Dis. 2020 Feb 18;20(1):153. doi: 10.1186/s12879-020-4871-9. BMC Infect Dis. 2020. PMID: 32070292 Free PMC article.
-
Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.Clin Infect Dis. 2019 Sep 27;69(8):1278-1287. doi: 10.1093/cid/ciy1105. Clin Infect Dis. 2019. PMID: 30759187 Free PMC article.
Cited by
-
Low treatment success rate among previously treated persons with drug-susceptible pulmonary tuberculosis in Kampala, Uganda.J Clin Tuberc Other Mycobact Dis. 2023 May 12;32:100375. doi: 10.1016/j.jctube.2023.100375. eCollection 2023 Aug. J Clin Tuberc Other Mycobact Dis. 2023. PMID: 37214160 Free PMC article.
-
Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.Cochrane Database Syst Rev. 2019 Jun 7;6(6):CD009593. doi: 10.1002/14651858.CD009593.pub4. Cochrane Database Syst Rev. 2019. Update in: Cochrane Database Syst Rev. 2021 Feb 22;2:CD009593. doi: 10.1002/14651858.CD009593.pub5. PMID: 31173647 Free PMC article. Updated.
-
Negative effects of undernutrition on sputum smear conversion and treatment success among retreatment cases in Uganda: A quasi-experimental study.J Clin Tuberc Other Mycobact Dis. 2024 Feb 24;35:100422. doi: 10.1016/j.jctube.2024.100422. eCollection 2024 May. J Clin Tuberc Other Mycobact Dis. 2024. PMID: 38434999 Free PMC article.
-
Treatment Outcomes of Tuberculosis Retreatment Case and Its Determinants in West Ethiopia.Open Respir Med J. 2019 Dec 31;13:58-64. doi: 10.2174/1874306401913010058. eCollection 2019. Open Respir Med J. 2019. PMID: 32175031 Free PMC article.
-
First Insight into a Nationwide Genotypic Diversity of Mycobacterium tuberculosis among Previously Treated Pulmonary Tuberculosis Cases in Benin, West Africa.Can J Infect Dis Med Microbiol. 2017;2017:3276240. doi: 10.1155/2017/3276240. Epub 2017 Jun 21. Can J Infect Dis Med Microbiol. 2017. PMID: 28713434 Free PMC article.
References
-
- World Health Organization. WHO/HTM/TB/2013.2. Geneva, Switzerland: World Health Organization; 2013. Definitions and reporting framework for tuberculosis—2013 revision. http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf.
-
- World Health Organization. Global Tuberculosis Report 2015. Geneva, Switzerland: World Health Organization; 2015. (WHO/HTM/TB/2015.22). http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?....
-
- World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes. Geneva, Switzerland: World Health Organization; 2009. (WHO/HTM/TB/2009.420). http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf.
-
- TB CARE I. International Standards for Tuberculosis Care. 3rd. The Hague, Netherlands: TB CARE I; 2014. http://www.who.int/tb/publications/ISTC_3rdEd.pdf?ua=1.
-
- World Health Organization. Tuberculosis Country Profiles: Benin. Geneva, Switzerland: World Health Organization; 2015. https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2....
LinkOut - more resources
Full Text Sources
Other Literature Sources